Avalo Therapeutics, Inc.

NASDAQ:AVTX

Biotechnology

Healthcare
$6.70 -2.18%

-$0.34 today

Market cap
$387.41M
Beta
0.82
P/E (TTM)
-3.6
EPS (TTM)
-$4.21
52W Low $4.50High $24.27

Volume 1.58M

Average 1.61M

AVTX Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

Avalo Therapeutics, Inc.NASDAQ: AVTX

Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026

Change in working capital turns negative

Q1 FY2026 change in working capital was -$1.08M, compared with $1.2M a year earlier. Trailing-twelve-month change in working capital was $1.57M.

Context

  • Change in working capital amounted to 6510.2% of revenue in FY2025, up 5442.6 pp from a year earlier.
  • Change in working capital increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly change in working capital holds near -$1.08M or moves back toward the trailing-twelve-month quarterly average of $391.25K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.08M-713.1% QoQ
Last fiscal yearDec 2025
$3.84M+181.6% YoY
LTMMar 2026
$1.57M+169.6% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-190.1%——
1 year+181.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
3.84M USD
Year-over-year change
+181.6%
4-year CAGR
+7.8%

Change in Working Capital vs competitors

How AVTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +169.6% is the 2nd highest of 9, against a peer median of -40.4%.
  • Change in working capital amounts to 2652.5% of revenue for AVTX, versus a peer median of 20.0%.
AVTX Competitors
Change in Working Capital for AVTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANABAnaptysBio, Inc.LTM Mar 2026$90.89M USD+54.3%—39.1%
IMUXImmunic, Inc.LTM Mar 2026$10.92M USD+78.7%-42.2%—
IFRXInflaRx N.V.LTM Mar 2026€8.45M EUR+450.5%—28812.5%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$6.56M USD-2.0%+47.8%—
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$2.98M USD-83.4%—35.6%
XNCRXencor, Inc.LTM Jun 2026$2.5M USD-91.4%-1.0%2.4%
QTTBQ32 Bio Inc.LTM Mar 2026$2.38M USD-78.9%—4.4%
SYRESpyre Therapeutics, Inc.LTM Sep 2026$2.19M USD-130.6%+2.5%2.4%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$1.57M USD+169.6%—2652.5%
ODTXOdyssey Therapeutics, Inc.—— ———
AGMBAgomAb Therapeutics N.V. American Depositary Shares—— ———
Peer median (excluding AVTX) —-40.4%+0.8%20.0%

Competitors are the stored peer set for AVTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(84.38M)(41.66M)(31.54M)(35.13M)(78.26M)
Depreciation & Amortization1.66M166K158K169K344K
Deferred Income Tax22K28K14K114K165K
Stock-Based Compensation8.17M7.55M3.48M5.85M13.62M
Change in Working Capital2.84M(60K)(9.24M)(4.71M)3.84M
Accounts Receivables1.12M2.88M1.78M(475K)0
Inventory(35K)18K20K00
Accounts Payables796K(487K)(2.44M)(163K)(146K)
Other Working Capital961K(2.47M)(8.61M)(4.07M)3.99M
Other Non-Cash Items794K7.22M6.46M(15.35M)8.83M
Operating Cash Flow(70.89M)(26.75M)(30.68M)(49.06M)(51.46M)
Capital Expenditures(113K)(95K)(158K)00
Acquisitions (Net)000356K0
Purchases of Investments0000(113.72M)
Sales of Investments000031.31M
Other Investing Activities0025K0690K
Investing Cash Flow(113K)(95K)(133K)356K(81.72M)
Debt Repayment32.9M(14.81M)(21.24M)00
Common Stock Issued71.93M107K46.22M115.63M15.1M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.93M067K60.22M(510K)
Financing Cash Flow106.76M(14.7M)25.04M175.85M14.59M
Effect of Forex Changes096K000
Net Change in Cash35.76M(41.45M)(5.77M)127.15M(118.59M)
Free Cash Flow(71.01M)(26.85M)(30.84M)(49.06M)(51.46M)

Avalo Therapeutics, Inc.

NASDAQ:AVTX

Intrinsic Alpha fair value

Locked

Current Price

$6.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.